Asuragen Targets Early Diagnosis and Treatment Outcome for Cancer Patients
News Jan 12, 2006
Asuragen, Inc. has announced its plan and direction for the future in biotechnology. Led by Matt Winkler, founder and CEO of Ambion, Inc., Asuragen, is comprised of three business units: Molecular Diagnostics (formerly Ambion Diagnostics, Inc.), Molecular Biology Services (formerly Ambion Services) and Discovery, an R&D focused unit.
Several key executives and research scientists from Ambion are also joining the company. The company will be funded with approximately $35M in proceeds from the December 23rd, $273M sale of Ambion's research products division to Applied Biosystems. This transaction is expected to close in late February.
"Ambion has been a significant leader in the development of enabling technologies for RNA research," Winkler said.
"Academic and industry scientists have used these technologies for research related to the diagnosis and intervention of disease."
"After 17 years of making tools for other scientists to study cancer, I wanted a chance to use those tools me to see if I could make a major impact on cancer diagnosis and treatment."
Asuragen will leverage the RNA expertise developed by Ambion to create diagnostic products that will enhance cancer patient care by facilitating early diagnosis and predicting treatment outcome.
The company has rights to a variety of Ambion and other intellectual properties as well as its own growing portfolio of patents and patent applications for preparing and analyzing nucleic acids within clinical samples.
Asuragen also has an R&D group with experience developing diagnostic assays, identifying biomarkers for diseases such as cancer, and creating technologies that facilitate purification and analysis of RNA and DNA.
Asuragen has the benefit of much of the RNA "know-how" that was Ambion's and has access for the diagnostic markets of Ambion's Intellectual Property.
Winkler said, "Asuragen has all the pieces in place to be a fully integrated molecular diagnostics company with the mission to deliver products and services that serve one of the fastest growing segments of the molecular diagnostics market."
"It is an exciting opportunity and a far cry from when I started Ambion in the loft of my house 17 years ago."
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018